Mycobacterium tuberculosis whole genome capturing method, primer group and kit
By designing specific primer combinations and kits, combining PCR amplification and high-throughput sequencing technology, the insufficient data in Mycobacterium tuberculosis whole genome sequencing and drug sensitivity detection was solved, and efficient and accurate genome amplification and Sequencing to support drug resistance studies.
Patent Information
- Application Number
- CN202411268446.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-11
AI Technical Summary
The prior art has problems with insufficient data and lack of a complete database in the whole genome sequencing and drug sensitivity detection of Mycobacterium tuberculosis, making it difficult to accurately diagnose and predict bacterial drug resistance.
A primer combination and kit for whole genome capture of M. tuberculosis, including 20 specific primers, combined with PCR amplification and high-throughput sequencing technology, has been designed to achieve the amplification of the whole genome of M. tuberculosis and Sequencing.
It improves the uniformity of genome coverage and amplification efficiency, can quickly and accurately detect the genomic sequence of Mycobacterium tuberculosis, and supports drug sensitivity detection and drug resistance research.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and in particular relates to a method, a primer set and a kit for capturing the whole genome of Mycobacterium tuberculosis. Background Art
[0002] Mycobacterium tuberculosis (MTB) is the pathogen of tuberculosis. Tuberculosis is a chronic infectious disease caused by infection with Mycobacterium tuberculosis, which seriously endangers human health and social development. The current prevention and control of tuberculosis faces huge challenges. Accurate diagnosis of Mycobacterium tuberculosis infection plays a key role in the prevention and control of tuberculosis. If the original clinical samples are directly subjected to conventional whole genome sequencing (WGS), accurate sequences can be provided within 24h to 48h, which is accurate and timely for determining bacterial gene mutation sites, and can also discover new mutation sites, and be applied to epidemiology and MTB resistance mechanism research. Although the resistance mechanism of MTB is not yet fully understood, and there is no complete database for drug sensitivity detection and phenotypic prediction after genome sequencing, whole genome sequencing can be integrated into the routine diagnostic workflow to gradually replace the drug sensitivity phenotypic detection technology in early diagnostic testing.
[0003] Whole genome sequencing (WGS) is a commonly used genotyping technology with high resolution. It can not only identify single nucleotide polymorphisms (SNPs) on the genome to determine the microevolution of MTB during transmission, but also obtain the entire sequence of the target genome and predict the resistance of most anti-tuberculosis drugs. Application of NGS in MTB drug resistance detection: NGS is widely used in clinical practice in MTB drug resistance detection due to its advantages of simplicity, speed, accuracy and reliability, especially for the detection of multidrug-resistant tuberculosis patients, which is the key to the effective treatment of drug-resistant Mycobacterium tuberculosis.
[0004] The whole genome sequencing technology is used to obtain the whole gene sequence of MTB, and the known MTB resistance mechanism is used to detect related resistance mutations at the whole genome level, so that the resistance detection based on molecular biology is no longer limited to one or several first-line drugs. Whole genome sequencing technology is often used in scientific research on drug resistance to discover new resistance sites and explain new resistance mechanisms.
[0005] Therefore, obtaining the complete genome of MTB is of great significance. Summary of the invention
[0006] To overcome the deficiencies of the prior art, the present invention aims to provide a method, a primer set and a kit for capturing the whole genome of Mycobacterium tuberculosis.
[0007] To achieve the above object, the present invention adopts the following technical solution:
[0008] The first aspect of the present invention provides a primer combination for whole genome amplification of Mycobacterium tuberculosis.
[0009] Further, the primer combination includes 20 primers designed for the Mycobacterium tuberculosis cell genome, and the 20 primers have the sequences shown by TTCGTCGA, CGATACCG, CGATCGTC, CTTCGTCG, CGAAGTCG, CGAATCG, CGAACTCG, CGATTCCG, CGATCAGC, GTTGACCG, GTTGTCGG, GTCGTCG, ATCGTCG, TCGTCGG, CGAACCG, GCGAACG, CGTACCG, CGTAGCG, CGTCGTA, and TATCGCG.
[0010] In the present invention, primer combinations and primers can be used interchangeably, and primers refer to short nucleic acid molecules. The primers disclosed in the present invention are between 7 and 8 nucleotides in length. Can be annealed with complementary target nucleic acid molecules by nucleic acid hybridization, forming a hybrid between the primer and the target nucleic acid chain. Primers can be extended along the target nucleic acid molecule by polymerase. Therefore, primers can be used to amplify target nucleic acid molecules, wherein the sequence of the primer is specific to the target nucleic acid molecule.
[0011] Target nucleic acid molecule refers to a nucleic acid molecule intended to be detected, quantitatively, qualitatively detected or a combination thereof. Nucleic acid molecules are not necessarily in a purified form. Various other nucleic acid molecules may also coexist with the target nucleic acid molecule. For example, the target nucleic acid molecule may be a specific nucleic acid molecule intended to be amplified. If desired, the purification or separation of the target nucleic acid molecule may be carried out by methods known to those skilled in the art, for example, using commercially available purification kits etc.
[0012] In some embodiments, primers and / or probes corresponding to sequences having more than 70% homology with the primer and / or probe sequences described in the present invention are also included in the protection scope of the present invention, that is, it can be understood that the primers and / or probes obtained after changes are made on the basis of the primers and / or probes provided by the present invention also fall within the protection scope of the present invention.
[0013] A second aspect of the present invention provides a kit.
[0014] Furthermore, the kit comprises the primer combination described in the first aspect of the present invention.
[0015] Furthermore, the kit also includes PCR amplification buffer, amplification enzyme, DTT, dNTP, pyrophosphatase, and nuclease-free pure water.
[0016] Furthermore, the amplification enzyme includes DNA polymerase and / or RNA polymerase.
[0017] Preferably, the amplification enzyme is a DNA polymerase.
[0018] Furthermore, the kit also includes instructions.
[0019] In the present invention, suitable amounts of one or more primers are provided in one or more containers, or fixed on a substrate, and the primers can be provided suspended in an aqueous solution, or, for example, as a freeze-dried or lyophilized powder. The container in which the nucleic acid is provided can be any conventional container capable of accommodating the provided form, such as a microcentrifuge tube, an ampoule or a bottle. The kit can contain labeled or unlabeled probes for detecting Mycobacterium tuberculosis sequences.
[0020] In some applications, one or more primers (as described above) may be provided in pre-measured single-use amounts in separate, typically disposable tubes or equivalent containers. Using such an arrangement, samples to be tested for the presence of digestive viruses may be added to separate tubes and amplified directly.
[0021] The amount of nucleic acid primers provided in the kit can be any suitable amount and can depend on the target market for the product. For example, if the kit is suitable for research or clinical applications, the amount of each nucleic acid primer provided can be an amount sufficient to initiate several PCR amplification reactions. General guidance on determining suitable amounts can be found in the literature of Innis et al., Sambrook et al., and Ausubel et al. The kit can contain more than two primers to facilitate PCR amplification of larger amounts of Mycobacterium tuberculosis nucleotide sequences.
[0022] In certain embodiments, the kit may contain the necessary reagents for performing a PCR amplification reaction, including DNA sample preparation reagents, enzymes for PCR, buffers, Mg 2+ and deoxyribonucleotides (dNTPs).
[0023] The PCR enzymes include DNA polymerase and / or RNA polymerase.
[0024] The DNA polymerase includes but is not limited to Taq, Bst, Vent, Phi29, Pfu, Tru, Tth, Tl1, Tac, Tne, Tma, Tih, Tf1, Pwo, Kod, Sac, Sso, Poc, Pab, Mth, Pho, ES4 DNA polymerase, and Klenow fragment.
[0025] dNTP is a nucleoside source for PCR-based DNA amplification, and dATP, dGTP, dCTP, and dTTP are necessary. In addition, dNTP can be chemically modified for use in the hot start method, for example, CleanAmp manufactured by TriLink BioTechnologies, Inc. can be used. TM dNTPs.
[0026] In PCR-based DNA amplification, Mg 2+ It is necessary as Mg 2+ Sources, including but not limited to MgCl 2 MgSO 4 wait.
[0027] In the present invention, the kit further comprises instructions, which may include guidance on obtaining samples and processing samples.
[0028] Furthermore, the kit may contain bacterial genomic DNA used as a positive control for PCR and sterile water used as a negative control.
[0029] When implementing the present invention, other necessary instruments include pipettes, pipette tips, 1.5 ml microtubes, and other instruments widely used in molecular biology experiments. Devices include PCR, clean benches, tube centrifuges, and other instruments widely used in molecular biology experiments.
[0030] The third aspect of the present invention provides a method for obtaining the complete genome sequence of Mycobacterium tuberculosis.
[0031] Furthermore, the method uses the primer combination described in the first aspect of the present invention to amplify the whole genome sequence of Mycobacterium tuberculosis.
[0032] Furthermore, the method comprises: using the primer combination described in the first aspect of the present invention to perform PCR amplification on the sample, recovering and purifying the amplified product, library amplification, library purification, library quality inspection and sequencing.
[0033] Furthermore, based on a total volume of 18 μL, the PCR amplification system includes: Reaction Mix 2 μL, PrimerMix 5 μL, dNTP Mix 2 μL, DTT 2 μL, DNA sample 1 ng to 1 μg, and the balance is water.
[0034] Furthermore, after the PCR amplification system was incubated at 95° C. for 5 min, 1 μL of DNA Polymerase and 1 μL of Pyrophosphatase were added.
[0035] Furthermore, after adding the above reagents, the reaction procedures of the PCR amplification are 42° C., 2 h; 65° C., 10 min; and stored at 4° C.
[0036] Furthermore, the samples include sputum, throat swabs, body fluids, secretions, puncture fluids, feces, etc.
[0037] In the present invention, those skilled in the art understand that after appropriate adjustment of the reaction conditions of the amplification reaction and / or the amount of each substance used, the purpose of detecting Mycobacterium tuberculosis in the sample to be tested from the subject can still be achieved. Therefore, the reaction conditions of the amplification reaction and / or the amount of each substance used as described above are not intended to limit the protection scope of the present invention. After appropriate adjustment, as long as the purpose of amplifying and detecting Mycobacterium tuberculosis in the sample to be tested can be achieved, the adjusted reaction conditions and / or the amount of each substance used will also fall within the protection scope of the present invention.
[0038] In some embodiments, the sample is derived from a clinical sample of a subject in need thereof, including but not limited to: cells, tissues, body fluids, such as: skin; mucosa; blood; blood derivatives or fractions, such as serum; extracted bile; biopsy or surgically removed tissue, including, for example, unfixed, frozen, fixed in formalin and / or embedded in paraffin; tears; breast milk; skin scrapings; surface washings; urine; sputum; cerebrospinal fluid; prostatic fluid; pus; bone marrow aspirate; middle ear effluent, bronchoalveolar lavage, tracheal aspirate, sputum, nasopharyngeal aspirate, oropharyngeal aspirate or saliva.
[0039] In some embodiments, the library amplification can be divided into two categories: variable temperature amplification and constant temperature amplification. Variable temperature amplification mainly includes classical polymerase chain reaction (PCR) and ligase chain reaction (LCR), while constant temperature amplification includes strand displacement amplification (SDA), rolling circle amplification (RCA), loop mediated amplification (LAMP), helicase-dependent isothermal DNA amplification (HDA), nucleic acid sequence-based amplification (NASBA), transcription-based amplification system (TAS). In the specific embodiment, PCR is used as an example to build a library.
[0040] In some embodiments, primers containing a tag sequence (Index) may be used in the library amplification. By using primers containing a tag sequence to amplify the ligation product, data from different sample sources in sequencing can be distinguished and the source of the sample can be identified. The design method of the tag sequence is conventionally known to those skilled in the art, and the design of primers containing a tag sequence (Index) is also conventionally known to those skilled in the art.
[0041] In some embodiments, the sequencing can be performed by a high-throughput sequencing platform including IlluminaNovaSeq, HiSeq X Ten, Illumina HiSeq, Illumina MiSeq, PacBio Sequel, 10×Genomics, and MGISEQ-2000.
[0042] In a specific embodiment of the present invention, the sequencing is performed by Illumina MiSeq platform.
[0043] A fourth aspect of the present invention provides a library for detecting Mycobacterium tuberculosis.
[0044] Furthermore, the library comprises the primer combination described in the first aspect of the present invention.
[0045] In some embodiments, the library refers to a collection of DNA or RNA samples that stores a large number of gene sequences. These samples are collected, classified, cataloged and labeled so that researchers can easily find and use them to study the function of genes or find clones of specific genes. The process of establishing a library is similar to establishing a library, both of which are for the efficient management and utilization of a large amount of information or material resources. In the detection of Mycobacterium tuberculosis, the library may contain a variety of gene sequences related to the bacteria, which helps to gain a deeper understanding of its biological characteristics, pathogenic mechanisms, drug resistance and other information.
[0046] The fifth aspect of the present invention provides use of the primer combination described in the first aspect of the present invention in preparing a product for amplifying or detecting a nucleic acid sequence of Mycobacterium tuberculosis.
[0047] The sixth aspect of the present invention provides use of the primer combination described in the first aspect of the present invention or the kit described in the second aspect of the present invention in amplifying the whole genome sequence of Mycobacterium tuberculosis or in sequencing Mycobacterium tuberculosis.
[0048] Compared with the prior art, the present invention has the following advantages and beneficial effects: the primer combination designed by the present invention has high amplification efficiency and uniform genome coverage. DETAILED DESCRIPTION
[0049] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0050] In each of the following examples, the equipment and materials used were from the following sources:
[0051] Bacterial DNA extraction kit: Tianlong bacterial genomic DNA extraction kit
[0052] Instrument: Thermo Qubit Instrument (Cat. No.: Q33238)
[0053] Reagent: Thermo Qubit 1X dsDNA HS (High Sensitivity) Quantitation Kit (Cat. No.: Q33231)
[0054] Illumina DNAPrep Library Preparation Kit (Cat. No.: TD502)
[0055] Example 1 Acquisition of the complete genome of Mycobacterium tuberculosis
[0056] 1. Experimental Materials
[0057] The reagent components used in the experiment, Reaction Mix, DNA Polymerase, and DTT, were from EquiPhi29 from ThermoFisher. TM DNA Polymerase (Cat. No. A39390); dNTP mix was from Thermo Fisher (Cat. No. R0192); Pyrophosphatase was from Thermo Fisher (Cat. No. EF0221); Nucleasa-free water was from Thermo Fisher (Cat. No. 2305233).
[0058] The primer sequences used in the experiment are shown in Table 1 and were synthesized by Sangon.
[0059] Table 1 Primer sequence information
[0060]
[0061]
[0062] 2. Sample nucleic acid extraction:
[0063] Extract according to the corresponding requirements and steps in the bacterial DNA extraction kit. The final DNA elution volume is recommended to be 20-50μL. The extracted tuberculosis DNA can be directly used for sequencing detection. If the tuberculosis DNA is not directly tested after extraction, it can also be stored at -80℃ for future use, but repeated freezing and thawing should be avoided.
[0064] 3. Whole genome capture:
[0065] (1) Thaw the components of this kit on ice or at 4°C in advance, mix thoroughly by inversion, and centrifuge briefly.
[0066] (2) Add the following reagents to a 0.2 mL thin-walled PCR tube without nucleic acid on ice:
[0067] Table 2 Reagent components
[0068]
[0069] (3) Gently mix the reaction solution and centrifuge briefly. Incubate at 95°C for 5 min. After incubation, place the product on ice immediately.
[0070] (4) Add the following reagents to the above mixture on ice:
[0071] Table 3 Reagents
[0072]
[0073] (5) Gently mix the above reaction solution and centrifuge briefly, and then amplify according to the following procedure:
[0074] Table 4 Primer amplification program
[0075]
[0076] (6) Add 40 μL ddHO to the above amplified product. 2 O, gently mix and briefly centrifuge before purification. If no subsequent experiments are performed, it can also be stored at -20℃ for future use.
[0077] 4. Product recovery
[0078] It is recommended to use 1.8 times the volume of Beijing Micro Future Purification Magnetic Beads to purify the above amplification products. The purified magnetic beads need to be placed at room temperature for 30 minutes and shaken to fully activate them, otherwise it will affect the purification recovery rate. The purified product can be used for subsequent library construction. If the subsequent experiment is not carried out directly, it can also be stored at -20℃ for future use.
[0079] 5. Purification
[0080] After the amplification reaction is completed, herpes zoster virus gene fragments of different sizes will be obtained in one tube of PCR reaction. After the experiment is completed, the 5 tubes of amplification products are concentrated in a 1.5mL EP tube. After purification and qubit quantification, the subsequent library construction experiment can be carried out directly.
[0081] (1) Add 250 μL AMPure XP beads; *Note: This step is 1,0x-1.5x AMPure XP beads.
[0082] (2) Oscillating at 1800 rpm for 2 min; incubating for 5 min;
[0083] (3) Place on the magnetic rack for 2 min or until clarified, then discard the supernatant;
[0084] (4) Add 500 μL of freshly prepared 80% ethanol, place on a magnetic stand for 30 seconds, and discard the supernatant;
[0085] (5) Repeat the above steps;
[0086] (6) Remove the remaining liquid with a 10 μL pipette tip;
[0087] (7) Dry on a magnetic rack for 2 min;
[0088] (8) Remove from the magnetic stand; add 40 μL RSB;
[0089] (9) Oscillating at 1800 rpm for 2 min, and then incubating at room temperature for 2 min;
[0090] (10) Place on a magnetic rack until the liquid becomes clear;
[0091] (11) Transfer 38 μL of supernatant to a new plate.
[0092] 6. Quantification
[0093] Operation process (reference document: QUICK REFERENCE-Qubit TM Assays(MAN0017210vA.0):
[0094] a) 1 μL dye reagent + 199 μL buffer, vortex mix to get the working solution, protect from light and set aside.
[0095] b) Add 1-20 μL of library to Qubit working solution, the final volume is 200 μL.
[0096] c) Vortex for 2-3 seconds and place at room temperature away from light for 2 minutes.
[0097] d) Place the Qubit on the plate and perform the assay.
[0098] Example 2 Library construction operation process
[0099] 1. DNA fragmentation
[0100] (1) Qubit quantification, add 2-30 μL DNA (1-500 ng) to the PCR tube;
[0101] *Note: For multiple samples, the concentration should be greater than 50 ng or less than 50 ng to facilitate subsequent PCR amplification.
[0102] (2) Add pure water to the sample well to make the total volume 30 μL;
[0103] (3) Vortex BLT10s to check whether the beads are completely suspended;
[0104] (4) Prepare the fragmentation main reaction solution. For each reaction, add 11 μL BLT and 111 μL TB. Vortex the main reaction solution to mix well.
[0105] (5) Add 20 μL of the main reaction solution to the PCR sample well and vortex to mix (a total of 50 μL);
[0106] (6) Place in PCR instrument and run TAG Program (reaction system: 50 μL / well): heat cover at 100°C; 55°C for 15 min; store at 10°C;
[0107] 2. Purification
[0108] (1) Add 10 μL of TSB to the fragmentation reaction solution, gently pipette and mix 10 times, and resuspend the beads;
[0109] *Note: TSB (check for precipitation) and TWB are stored at 15-30°C and returned to room temperature before use.
[0110] (2) Run the following program in a PCR instrument: (set the hot cover to 100°C, the system to 60 μL); 37°C, 15 min; store at 10°C;
[0111] (3) Place the reaction tube in a magnetic rack, wait for the liquid to become clear (approximately 3 min), and then aspirate and discard the supernatant;
[0112] (4) Remove the reaction tube from the magnetic rack, slowly add 100 μL TWB, resuspend the magnetic beads, place the reaction tube in the magnetic rack, wait for the liquid to clarify (about 3 min), aspirate and discard the supernatant;
[0113] (5) Repeat step (4) once;
[0114] (6) Remove the reaction tube from the magnetic rack, slowly add 100 μL TWB, resuspend the magnetic beads, and place the reaction tube in the magnetic rack to wait for the liquid to clarify (about 3 minutes); the reaction tube remains on the magnetic rack until step (2) of amplifying the fragmented and labeled DNA is performed.
[0115] 3. Amplify fragmented and labeled DNA
[0116] 3.1 Prepare the PCR master reaction solution (for each sample): 22 μL EPM + 22 μL water, vortex to mix, and shake gently;
[0117] *Note: EPM: Thaw on ice. Invert to mix and centrifuge briefly;
[0118] DNAAdapter: Thaw at room temperature. For tubes, vortex and centrifuge briefly. For well plates, centrifuge briefly before use.
[0119] 3.2 Remove the supernatant on the magnetic rack and immediately add 40 μL of PCR master reaction solution to the sample well and mix well;
[0120] 3.3 For IndexAdapter Tubes, add 5 μL i7 adapter and 5 μL i5 adapter respectively and mix by pipetting;
[0121] 3.4 Run PCR program: set the hot cover to 100°C, the system to 50 μL, and the PCR program as shown in Tables 5 and 6.
[0122] Table 5 Correspondence between DNA starting amount and PCR cycle number
[0123] Total DNA input amount (ng) PCR cycle number (X) 1-9 12 10-24 8 25-49 6 50-99 5 100-500 5 Blood / Saliva 5
[0124] Table 6 PCR program
[0125]
[0126] 4. Library purification
[0127] 4.1 Centrifuge the reaction tube and place it in a magnetic rack to wait for the liquid to clarify (about 5 minutes);
[0128] 4.2 Pipette and transfer 45 μL of supernatant to a new centrifuge tube;
[0129] 4.3 Vortex and resuspend SPB thoroughly;
[0130] *Note: SPB needs to be returned to room temperature and vortexed before use;
[0131] 4.4 For 100-500 ng of starting DNA, perform the following steps:
[0132] a. Add 40 μL HO to the reaction tube containing the supernatant. 2 O;
[0133] b. Add 45 μL SPB to the reaction tube, mix thoroughly, and incubate at room temperature for 5 min;
[0134] c. Place the reaction tube on the magnetic rack and wait for the liquid to clarify (about 5 minutes);
[0135] d. During the incubation period, vortex the SPB thoroughly and then take 15 μL and add it to a new centrifuge tube;
[0136] e. Transfer 125 μL of supernatant from the reaction tube on the magnetic stand to a new centrifuge tube (containing 15 μL SPB) and mix thoroughly;
[0137] 4.5 For <100 ng of starting DNA, perform the following steps: add 81 μL SPB to the reaction tube containing the supernatant and mix thoroughly;
[0138] 4.6 Incubate at room temperature for 5 minutes, place the reaction tube on a magnetic rack, wait for the liquid to clarify (about 5 minutes), aspirate and discard the supernatant;
[0139] 4.7 Add 200 μL of freshly prepared 80% ethanol to the reaction tube, incubate for 30 seconds, discard the supernatant, and repeat this step once;
[0140] 4.8 Keep the reaction tube on the magnetic rack, aspirate and discard the residual ethanol in the reaction tube, and dry it for 5 minutes;
[0141] 4.9 Remove the reaction tube from the magnetic rack, add 32 μL RSB to resuspend the magnetic beads, and incubate at room temperature for 2 minutes;
[0142] 4.10 Place the reaction tube on the magnetic rack, wait for the liquid to clarify (about 2 minutes), and transfer 30 μL of the supernatant to a new centrifuge tube.
[0143] 5. Library quality control
[0144] 5.1 Take 1 μL of the constructed library and run it on Agilent Bioanalyzer 2100 (optional);
[0145] 5.2Qubit quantification;
[0146] Molar concentration (nM) = mass concentration (ng / μL) * 10 to the sixth power / (660 * average fragment length of the library)
[0147] Example 3 MiSeq machine operation
[0148] 1. Dilution and denaturation of the library
[0149] 1) Recommended concentrations for use on the machine are shown in Table 7.
[0150] Table 7 Recommended concentrations for use on the machine
[0151] Reagents and types Sample initial concentration Library concentration range MiSeqv3 Kit 4nM 6-20pM MiSeqv2 Kit 4nM 6-20pM MiSeqv2 Kit 2nM 6-10pM
[0152] 2) Experimental preparation:
[0153] 1NNaOH, PCR grade water, HT1, pipettes and tips, vortex shaker, handheld centrifuge.
[0154] 3) Operation steps:
[0155] 1.20 μL 1N NaOH + 80 μL ultrapure water to get 0.2N NaOH.
[0156] 2. Vortex for 3-5 seconds, centrifuge briefly, and repeat once.
[0157] 3.5 μL 4 nM or 2 nM library + 5 μL 0.2N NaOH.
[0158] 4. Vortex for 3-5 seconds, centrifuge briefly, and repeat once.
[0159] 5. Denature at room temperature for 5-10 minutes.
[0160] 6. Add 90 μL of ice-cold HT19.
[0161] 7. Vortex for 5-10 seconds and centrifuge briefly. Repeat once.
[0162] 8. According to the library type and optimized loading concentration, perform the second dilution according to the following table:
[0163] Table 8 4nM starting concentration library
[0164] Computer concentration 6pM 8pM 10pM 12pM 15pM 20pM 20pM library 180μL 240μL 300μL 360μL 450μL 600μL Ice precooling HT1 420μL 360μL 300μL 240μL 450μL 0μL
[0165] Table 9 2nM starting concentration library
[0166] Computer concentration 6pM 8pM 10pM 20pM library 360μL 480μL 600μL Ice precooling HT1 240μL 120μL 0μL
[0167] 9. Place the diluted and denatured library on ice or in a 2-8°C refrigerator, ready for use on the machine.
[0168] 2. Experimental Results
[0169] According to the genome sequence of Mycobacterium tuberculosis cells, 16 experimental groups were designed. Sequencing experiments were performed in all 16 experimental groups. The sequencing results were subjected to bioinformatics analysis and the data are shown in the following table.
[0170] Table 10 Sequencing results
[0171]
[0172]
[0173] In the names of the primers used in the present invention: M represents Mycobacterium tuberculosis; R represents random primers; T represents designed primers; -50: the final concentration of the input primers is 50 μM; for example: MR-50: the input volume of random primers is 50 μM; MT10-50: the input volume of 10 designed primers is 50 μM in total; MT15-100: the input volume of 15 designed primers is 100 μM in total;
[0174] 37rv means that the reference tuberculosis sequence name of this experiment is h37rv, with a total length of 4474617bp. For example: 2.43: means that the tuberculosis matching rate of the experimental group MR-50 is 2.43%, that is, the matching rate of the gene sequence reads obtained by using this set of primers and the reference tuberculosis genome h37rv reads is 2.43%.
[0175] human: Reference to the human genome. For example, 20.41 means that the human genome alignment rate of the experimental group MR-50 is 20.41%, that is, the alignment rate of the gene sequence reads obtained using this set of primers with the reference human genome reads is 20.41%.
[0176] Coverage: How many bases are covered in the experimental group, with the full length of 4474617bp of the tuberculosis bacillus sequence name h37rv as a reference. For example: 3514115 means that the coverage of the experimental group MR-50 is 3514115, that is, the bases of the gene sequence obtained by this set of primers are covered with the tuberculosis bacillus sequence name h37rv as a reference, and 3514115bp of bases are covered.
[0177] Summary: According to the data in the table above, the experimental results of primer set 8 MT20-50 are the best. This set of primers is designed with 20 primers and an input volume of 50 μM, with a tuberculosis matching rate of 10.36%, a human genome matching rate of 11.00%, and a coverage of 4165768 bp.
[0178] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. A primer combination for whole genome amplification of Mycobacterium tuberculosis, characterized in that: The primer combination includes 20 primers designed for the Mycobacterium tuberculosis cell genome, and the 20 primers have the sequences shown by TTCGTCGA, CGATACCG, CGATCGTC, CTTCGTCG, CGAAGTCG, CGAATCGCG, CGAACTCG, CGATTCCG, CGATCAGC, GTTGACCG, GTTGTCGG, GTCGTCG, ATCGTCG, TCGTCGG, CGAACCG, GCGAACG, CGTACCG, CGTAGCG, CGTCGTA, and TATCGCG.
2. A kit, characterized in that: The kit comprises the primer combination according to claim 1.
3. The kit according to claim 2, characterized in that The kit also includes PCR amplification buffer, amplification enzyme, DTT, dNTP, pyrophosphatase, and nuclease-free pure water; Preferably, the amplification enzyme comprises DNA polymerase and / or RNA polymerase; Preferably, the amplification enzyme is a DNA polymerase; Preferably, the kit further comprises instructions.
4. A method for obtaining the complete genome sequence of Mycobacterium tuberculosis, characterized in that: The method uses the primer combination described in claim 1 to amplify the whole genome sequence of Mycobacterium tuberculosis.
5. The method according to claim 4, characterized in that The method comprises: using the primer combination described in claim 1 to perform PCR amplification on the sample, recovering and purifying the amplified product, library amplification, library purification, library quality inspection and sequencing.
6. The method according to claim 4, characterized in that Based on a total volume of 18 μL, the PCR amplification system includes: Reaction Mix 2 μL, Primer Mix 5 μL, dNTP Mix 2 μL, DTT 2 μL, DNA sample 1 ng to 1 μg, and the balance is water; Preferably, after the PCR amplification system is incubated at 95°C for 5 min, 1 μL of DNA Polymerase and 1 μL of Pyrophosphatase are added; Preferably, the reaction procedure of the PCR amplification is 42° C., 2 h; 65° C., 10 min; and storage at 4° C.
7. The method according to claim 4, characterized in that The samples include sputum, throat swabs, body fluids, secretions, puncture fluids, feces, etc.
8. A library for detecting Mycobacterium tuberculosis, characterized in that: The library comprises the primer combination of claim 1.
9. Use of the primer combination according to claim 1 in preparing a product for amplifying or detecting a nucleic acid sequence of Mycobacterium tuberculosis.
10. Use of the primer combination according to claim 1 or the kit according to claim 2 in amplifying the whole genome sequence of Mycobacterium tuberculosis or in sequencing Mycobacterium tuberculosis.
Citation Information
Patent Citations
Method for detecting mycobacterium tuberculosis and special-purpose primers therefor
CN102787161A
Nucleic acid sequence and kit for mycobacterium tuberculosis composite strain detection, detection method of mycobacterium tuberculosis composite strain and application of nucleic acid sequence in mycobacterium tuberculosis composite strain detection
CN110819724A
Rapid identification of bacterial pathogens
CN113646445A
Primer library, kit and detection method for detecting drug-resistant genes of mycobacteria and / or tuberculosis
CN116377095A
